1. Scrip
  2. >>Business
  3. >>Financing

Mirador Lands $400m To Pursue I&I Precision Medicine Approach

 
• By Joseph Haas

Ex-Prometheus team will use its big data platform to validate targets, select indications and optimize trial enrollment in the development of precision therapies for inflammatory and immune disorders.

Vantage point
Mirador expects a unique vantage point to address IBD indications • Source: Shutterstock

When talking about start-up Mirador Therapeutics and its approach to precision medicine for inflammation and immunology, CEO and chairman Mark McKenna mentioned getting “the band back together” multiple times, referring to himself and several high-ranking execs who positioned Prometheus Biosciences, Inc. for a $10.8bn buyout by Merck & Co., Inc. last April on the strength of a Phase III-ready TL1A inhibitor for inflammatory bowel disease.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.